Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

A drug that Novo Nordisk acquired to expand its prospects ... Targeting it for obesity was validated by rimonabant (brand name Acomplia), a Sanofi drug approved in Europe in 2006.